ФЕРЕЙН FERANE

Ferein Joint Stock Company

We take care of your health!

PRODUCT CATALOGUE



CONTENTS

Glucocorticoids	H02AB02	Dexamethasone 4 mg/ml solution for injections in 1 ml ampoules in packs No. 5x5	13
Gynecologicals	G02AB01	Methylergometrine 0.2 mg/ml solution for intravenous and intramuscular injection in 1 ml ampoules in pack No. 5x2	15
Haematological agents	B06AB	Diavitol solution for injections in 5 ml ampoules in pack No. 5x2	15
Hemostatics	B02BX01	Etamsylate 125 mg/ml solution for injections in 2 ml ampoules in pack No. 5x2	15
Hypnotics and sedatives	N05CM09	Valerian tincture for oral use, in 50 ml vials in pack No. 1	16
Hypnotics and sedatives	N05CM	Peony tincture in 50 ml vials in pack No. 1	16
Hypnotics and sedatives	N05CM	Leonurus tincture for oral use, in 50 ml vials in pack No. 1	16
Hypnotics and sedatives	N05CM	Sedanol tincture for oral use, in 50 ml vials in pack No. 1	17
Hypnotics and sedatives	N05CM	Heartdrops 50 ml tincture for oral use in pack No. 1	17
Iron preparations	B03AE10	Diaferrum capsules in jars No. 30 in pack No. 1	17
Irrigating solutions	B05CB01	Sodium chloride 9 mg/ml solution for injections in 5 ml ampoules in pack No. 5x2	18
Mouth preparations for topical use	A01AD	Rotatit liquid extract for topical use for treatment of infections of throat and mouth in 50 ml vials in pack No. 1	18
Mouth preparations for topical use	A01AD	Rotatit-PLUS tincture for topical use for treatment of infections of throat and mouth in 50 ml vials in pack No. 1	18
Posterior pituitary lobe hormones	H01BB02	Oxytocin 5 IU/ml solution for intravenous and intramuscular injection in 1 ml ampoules in pack No. 5x2	19
Preparations for treatmwent of wounds and ulcers	D03AX	Diavitol gel for topical use in 30 g tube, in 30 g jar in pack No. 1	19
Solvents and diluting agents, including irrigating solutions	V07AB	Water solvent for preparation of drug dosage forms for injections, in 5 ml ampoules in pack No. 5x2.	20
Throat preparations	R02AA	Calendula tincture for topical use for treatment of infections of throat and mouth in 50 ml vials in pack No. 1	20
Vitamin B1 and in combination with vitamin B6 and B12	A11DB	B-Gamma solution for intramuscular injection in 2 ml ampoules in pack No. 5x2	20
X-ray contrast media containing barium sulfate	V08BA01	Diabar 200 g suspension for oral use, in bottles or vials in pack No. 1	21
Medical products		Sveton 100 ml, 240 ml solution for contact lenses of all types in pack No. 1	21
Biologically active additives		Yantarin capsules 500 mg in bottle No. 30	22

METOCLOPRAMIDE

5 mg/ml solution for intravenous and intramuscular injection, in 2 ml ampoules in pack No. 5x2

Active substance per ampoule (2 ml of the solution).
Metoclopramide hydrochloride – 10 mg.

Therapeutic indications

To minimize the risk of developing neurological disorders and other adverse reactions; it is necessary to limit the course of metoclopramide use to 5 days.

Metoclopramide should no longer be used in case of chronic conditions such as gastroparesis, dyspepsia, gastroesophageal reflux disease or during surgery and radiological procedures.

Adult use:

For prevention of postoperative nausea and vomiting associated with chemotherapy.

For symptomatic treatment of nausea and vomiting, including nausea and vomiting in case of acute migraines.

For prevention of nausea and vomiting induced by radiation therapy.

The injection course of treatment should be as short as possible. It is necessary to carry out the patient crossover to the oral or rectal route of entry as soon as possible.

Children aged 1 to 18:

For prevention of delayed (non-acute) nausea and vomiting due to chemotherapy as a second choice drug. The maximum treatment course is 5 days.

For treatment of established postoperative nausea and vomiting as a second choice drug. The maximum treatment course is 48 hours.

AMIKACIN

250 mg/ml solution for intravenous and intramuscular injection in 2 ml, ampoules in packs No. 5x2

Active substance per ampoule: amikacin (as sulphate) – 500 mg.

Therapeutic indications

Amikacin is indicated in the short-term treatment of serious infections due to sensitive Gram-negative organisms.

The drug is also indicated for the treatment of staphylococcal diseases or suspected staphylococcal infections.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

BIFIDUMBAKTERIN DRY

5 doses of lyophilized powder for preparation of suspension for oral and topical use, in vials in packs No. 6

Contents per vial. 5 doses of the drug.

1 dose of the drug contains: *Bifidobacterium bifidum* 1 or 791 strain of viable bacteria lyophilized in the culture medium – no less than 10^7 CFU.

The culture medium consists of yeast autolysate, casein enzymatic hydrolyzate, lactose monohydrate, sodium chloride, L-cystine, food agar, purified water.

Therapeutic indications

Bifidumbacterin dry is indicated as an adjuvant for symptomatic treatment of diarrhea, and as an adjunct to fluid replacement and/or dietary measures for adults and children.

The drug can be used in children (including premature babies) since the first days of life.

Bifidumbacterin dry is used to restore microbiological balance in the intestinal tract:

- during acute and chronic inflammatory diseases of large and small intestinal tracts of children and adults caused by microflora imbalance with bifidobacteria deficiency;
- in case of intestinal dysfunctions after antibacterial and radiation therapy;
- during the combined therapy of patients with acute intestinal infections of bacterial and viral nature, convalescents with intestinal dysfunction symptoms, for prevention of intestinal dysfunction during antibacterial therapy of children with pyoinflammatory diseases;
- for prevention of intestinal dysfunctions of premature babies, as well as for children during the neonatal period with early crossover to artificial feeding.

Bifidumbacterin dry is used:

- for normalization of vaginal microbiocenosis during the combined therapy of bacterial colpitis, for pregnant women among others.

DIALACT

5x10^8 CFU (5 doses) of lyophilized powder for preparation of suspension for oral use, in vials in packs No. 6

Active substance per vial.

5 doses of the drug. 1 dose of the drug contains: *Lactobacillus acidophilus* Ke-10 strain of viable bacteria lyophilized in the culture medium – no less than 10^8 CFU.

Therapeutic indications

Prevention and supportive treatment of diarrhea caused by viral and bacterial gastrointestinal tract infections of infants, children and adults. Traveller's diarrhea. Diarrhea accompanied with the use of broad-spectrum antibiotics and chemotherapeutic agents. Diarrhea accompanied by radiation therapy of the abdominal cavity and pelvic organs. In case of acute and chronic diseases of large and small intestinal tracts (colitis, enterocolitis) caused by intestinal microflora dysbiosis.

BIOFLOR

solution for oral use in bottles or 100 ml, 250 ml vials in pack No. 1

Active substance per 100 ml: E.coli M-17* no less than 100×10^8 of living cells at the moment of preparation and no less than 100×10^7 of living cells at the end of shelf life.

Active substance per 250 ml: E.coli M-17* no less than 250×10^8 of living cells at the moment of preparation and no less than 250×10^7 of living cells at the end of shelf life.

Therapeutic indications

Bioflor is indicated during the combined therapy of:

- chronic gastrointestinal tract diseases (nonspecific and specific chronic colitis and enterocolitis accompanied by diarrheal syndrome);
- gastrointestinal disorders caused by the intestinal microflora imbalance;
- in convalescents after acute intestinal infections.

Use by children

Bioflor as a liquid drug dosage form is intended for use in children from 6 months of age.

HALOPERIDOL

5 mg/ml solution for intramuscular injection i
n 1 ml ampoules, in blister packs No. 5x2, No. 5x5

Active substance per ampoule (1 ml of the solution):
5 mg of haloperidol.

Therapeutic indications

Rapid relief of acute psychomotor agitation associated with mental disorder or manic episode in bipolar disorder of type I, when oral therapy is not applicable.

Urgent treatment of delirious syndrome, when non-pharmacological methods have failed.

Treatment of mild to moderate Huntington's chorea when drugs are ineffective or not tolerated by patients, and oral therapy is not used.

Mono- or combined prevention of moderate and high risk of postoperative nausea and vomiting when other drugs are ineffective or not tolerated by patients.

Combined treatment of postoperative nausea and vomiting when other drugs are ineffective or not tolerated by patients.

VENORELAX

tincture for oral use in 50 ml vials in pack No. 1

Active substance. Ethanolic extract from horse chestnut seeds with the ratio of 1:5.

Therapeutic indications

Symptomatic treatment of chronic venous insufficiency effects of the lower extremities such as varicose veins, swelling, fatigue, heaviness, pain, itching, tension and cramps of the calf muscles.

ADRENALINE

1.82 mg/ml solution for injections in 1 ml ampoules in pack No. 5x2

Active substance: epinephrine hydrotartrate – 1.82 mg, which is attributable to 1 mg of Adrenaline (Epinephrine).

Therapeutic indications

Instant-type allergic reactions (including urticaria, angioedema, anaphylactic shock) developing with the use of drugs, serums, as a result of blood transfusion and food consumption, insect bites or injections of other allergens, as well as idiopathic anaphylaxis and exercise-induced anaphylaxis.

Bronchial asthma (rapid relief of symptoms), bronchospasm under anaesthetic condition.

Symptomatic arterial hypotension.

Hypoglycemic coma due to insulin overdose.

Asystole, cardiac arrest.

III degree atrioventricular block (developed acutely).

The need to prolong the action of topical anaesthetics.

NORADRENALINE

concentrate for 2.0 mg/ml solution for intravenous injection in 4 ml ampoules in pack No. 5x2

Active substance: noradrenaline tartrate (as noradrenaline tartrate monohydrate – 2.1 mg) – 2.0 mg/ml.

Therapeutic indications

Noradrenaline is indicated to restore blood pressure during an acute decrease, except for hypotension caused by hypovolemia.

HAWTHORN TINCTURE

tincture for oral use in 50 ml vials in pack No. 1

Active substance. Ethanolic extract from hawthorn berries with the ratio of 1:10. Extractant – 70% ethyl alcohol (v/v).

Therapeutic indications

During the combined therapy of functional cardiac activity and nervous system disorders (neurasthenia). The use for the indicated purposes is based only on the experience of long-term use.



DOPAMINE

concentrate for 5 mg/ml, 40 mg/ml solution for infusions in 5 ml ampoules in pack No. 5x2

One ampoule of the concentrate for 40 mg/ml solution for infusions contains the following active substance: dopamine hydrochloride – 200 mg.

Therapeutic indications

Shock of various origins: cardiogenic, post-surgery, infectious-toxic, anaphylactic, hypovolemic (after circulating blood volume restoration).
Acute cardiovascular failure.
Syndrome of the “low-minute blood circulation volume” in cardiac surgery patients.

COUGH SYRUP WITH POLEMONIUM AND LIQUORICE

for oral use in bottles or 250 ml vials in pack No. 1

Active substances per 250 ml:

Dense extract of Liquorice root (DER: with the ratio of 4 – 4.5:1; extractant – water) – 5 g.

Liquid extract of Polemonium rootstocks with roots (DER: with the ratio of 1:3.6; extractant – 70% ethyl alcohol) – 17.5 g.

Therapeutic indications

As an expectorant during the combined therapy of acute respiratory diseases.

The scope of the drug use is based only on the experience of traditional long-term use of herbal components constituting the drug.

LIQUORICE ROOTS

syrup in bottles or 250 ml vials in pack No. 1

Active substance per 250 ml:

Dense extract of Liquorice root (DER: with the ratio of 4 – 4.5:1; extractant – water) – 12.5 g.

Therapeutic indications

As an expectorant during the combined therapy of acute respiratory diseases.

As a secondary agent during the combined therapy of functional gastrointestinal tract disorders (dyspepsia).

The use for the indicated purposes is based only on the experience of long-term use.

CHEST ELIXIR

solution for oral use in 50 ml vials in pack No. 1

Active substances per 50 ml:

Dense extract of Liquorice root (DER: with the ratio of 4 – 4.5:1; extractant – water) – 10.35 g.

Ammonia concentrated solution – 0.69 g.

Therapeutic indications

As an expectorant during the combined therapy of acute respiratory diseases followed by cough.

MUCALTIN-FEREIN

50 mg pills in blister pack No. 10x2

Active substance per pill: Mucaltin (dry extract of Althaea officinalis grass containing the amounts of reducing monosaccharides of no less than 8.0% and polysaccharide complex of no less than 50.0%; DER: with the ratio of (8-12):1, extractant – purified water) – 50 mg.

Therapeutic indications

During the combined therapy of inflammatory diseases of upper respiratory tracts (pharynx, larynx) followed by dry and irritating cough.

Mucaltin is a traditional herbal drug intended for use for the indicated purposes based only on the long-term use.

ARALIA TINCTURE

tincture for oral use in 50 ml vials in pack No. 1

Active substance. Ethanolic extract from chopped Manchurian aralia roots with a root-to-extract ratio of 1:5.

Therapeutic indications

Physical and mental over-fatigue, asthenic conditions, during the combined therapy of erectile dysfunction of neurasthenic genesis.

ELEUTEROCOCUS

liquid extract in 50 ml vials in pack No. 1

Active substance. Ethanolic extract from rootstocks with Eleuterococus roots at the ratio of 1:1. Contains no less than 33% of ethyl alcohol.

Therapeutic indications

The extract is indicated as a tonic for asthenic conditions, physical and mental over-fatigue.

PREDNISOLONE-FEREIN

30 mg/ml solution for intravenous and intramuscular injection in 1 ml ampoules in packs No. 5x2

Active substance per ampoule. Prednisolone as prednisolone sodium phosphate – 30 mg.

Therapeutic indications

Prednisolone is indicated for emergenc y therapy under conditions requiring rapid glucocorticosteroids concentration increase in the body:

States of shock (ambustial, traumatic, surgical, toxic, cardiogenic) – with ineffectiveness of vasoconstrictor and plasma-substituting drugs and other symptomatic therapy.

Allergic reactions (acute severe forms), posttransfusion shock, anaphylactic shock, allergic shock reactions.

Cerebral edema (following brain tumor or associated with surgery, radiation therapy or head trauma among others).

Bronchial asthma (severe form), status asthmaticus.

Systemic connective tissue diseases (systemic lupus erythematosus, rheumatoid arthritis).

Acute adrenal insufficiency.

Thyroid crisis.

Acute hepatitis, hepatic coma.

Reduction of inflammations and prevention of scarry strictures (in case of poisoning with escharotics).

DEXAMETHASONE

4 mg/ml solution for injections in 1 ml ampoules in packs No. 5x5

Active substance. Dexamethasone phosphate as dexamethasone sodium phosphate – 4.0 mg.

Therapeutic indications

Dexamethasone is indicated intravenously or intramuscularly in urgent cases, as well as when oral use is impossible in the following conditions:

Endocrine disorders: replacement therapy of primary or secondary (pituitary) adrenal insufficiency (hydrocortisone or cortisone are the drugs of choice, synthetic analogues can be used together with mineralocorticoids, if necessary; joint use with mineralocorticoids is extremely important in pediatric practice);

Endocrine disorders: replacement therapy of primary or secondary (pituitary) adrenal insufficiency (hydrocortisone or cortisone are the drugs of choice, synthetic analogues can be used together with mineralocorticoids, if necessary; joint use with mineralocorticoids is extremely important in pediatric practice); acute adrenal insufficiency (hydrocortisone or cortisone are the drugs of choice; it may be necessary to use it together with mineralocorticoids, especially in case of use of synthetic analogues); before surgery and in cases of serious injuries or illness in patients with the diagnosed adrenal insufficiency or undetermined adrenocortical stores; shock resistant to conventional therapy under present or suspected adrenal insufficiency; congenital adrenal hyperplasia; non-suppurative thyroid gland inflammation; hypercalcaemia caused by cancerous lesion.

Rheumatic diseases: as an adjuvant therapy for short-term use (for removing the patient from an acute condition or under disease recurrence) in: post-traumatic osteoarthritis; synovitis with osteoarthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (low-dose supportive therapy may be required in some cases); epicondylitis; acute nonspecific tendosynovitis; acute gouty arthritis; psoriatic arthritis; rheumatoid spondylitis.

Collagenoses: during the recurrence or as the supportive therapy for: systemic lupus erythematosus; acute rheumatic myocarditis in some cases.

Skin diseases: pemphigus; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative dermatitis; bullous dermatitis herpetiformis; severe seborrheic dermatitis; severe psoriasis; fungoid mycosis.

Allergic diseases: control over severe or disabling allergic conditions, which do not respond to conventional treatments: bronchial asthma; contact dermatitis; atopic dermatitis; serum disease; chronic or seasonal allergic rhinitis; allergy to medications; urticaria after blood transfusion; acute non-infectious laryngeal edema (epinephrine is the drug of choice).

Eye diseases: severe acute and chronic allergic and inflammatory processes involving eye damage: eye damage caused by Herpes zoster; iritis, iridocyclitis; chorioretinitis; diffuse posterior uveitis and choroiditis; optic neuritis; sympathetic ophthalmia; anterior segment inflammation; allergic conjunctivitis keratitis; allergic marginal corneal ulcer, severe inflammatory processes after eye injuries and surgeries.
Gastrointestinal diseases: for patient removal from the critical period involving ulcerative colitis (systemic treatment); Crohn's disease (systemic treatment).
Respiratory tract diseases: sarcoidosis; berylliosis; focal or disseminated pulmonary tuberculosis (together with the appropriate anti-tuberculosis chemotherapy); Loeffler's syndrome, which is not amenable to the treatment under other methods; aspiration pneumonitis.
Hematological diseases: acquired (autoimmune) hemolytic anemia; idiopathic thrombocytopenic purpura in adults (DO NOT ADMINISTER INTRAMUSCULARLY!!!); secondary thrombocytopenia in adults; erythroblastopenia (erythrocytic anemia); congenital (erythroid) hypoplastic anemia.
Oncological diseases: palliative treatment of leukemia and lymphoma in adults; acute leukemia in children.
Conditions accompanied by edema: urine output initiation or decrease in proteinuria in idiopathic nephrotic syndrome (without uremia) and renal abnormality in systemic lupus erythematosus.
Diagnostic tests for adrenotropism
Cerebral edema: in primary or metastatic brain tumors, traumatic brain injury, neurosurgical intervention, cerebral hemorrhage, encephalitis, meningitis.
Other indications: tuberculous meningitis with subarachnoid blockade or threatened blockade (together with the appropriate anti-tuberculosis therapy); trichinosis with neurological symptoms or myocardial trichinosis.
Indications for intra-articular injection or injection into soft tissues: as an adjuvant therapy for short-term use (for the purpose of removing the patient from an acute condition or under disease recurrence) in: rheumatoid arthritis (severe single joint inflammation); synovitis with osteoarthritis; acute and subacute bursitis; acute gouty arthritis; epicondylitis; acute nonspecific tendosynovitis; post-traumatic osteoarthritis.
Local administration (injection into the lesion site): keloid lesions; localized hypertrophic, inflammatory and infiltrated lesions in shingles, psoriasis, granuloma annulare; discoid lupus lichen; Oppenheim's lipoid atrophic dermatitis; localized alopecia.

МЕТИЛЭРГОМЕТРИН

0.2 mg/ml solution for intravenous and intramuscular injection in 1 ml ampoules in pack No. 5x2

Active substance: methylergometrine maleate – 0.2 mg.

Therapeutic indications

Uterine atony, bleeding and subinvolution of the uterus after placenta separation.

Prevention of uterine bleeding at the second labor stage after the front shoulder birthing.



DIAVITOL

solution for injections in 5 ml ampoules in pack No. 5x2

Active substance per ampoule

Diavitol- Ferein - 5 ml

The drug is an ultrafiltrate of the blood of veal calves.

Therapeutic indications

The drug is indicated in the combined therapy of:

Metabolic and vascular brain disorders (including dementia).

Peripheral (arterial and venous) vascular disorders and their consequences

(arterial angiopathy, trophic ulcers).

Diabetic polyneuropathy.

Ulcers of various etiologies, burns, trophic disorders (bed sores), wound healing disorders.

ETAMSYLATE

125 mg/ml solution for injections in 2 ml ampoules in pack No. 5x2

Active substance per ampoul: etamsylate – 250 mg.

Therapeutic indications

Capillary bleeding of various etiologies, especially if the bleeding

is caused by endothelium damage:

1. Prevention and control over bleeding during surgeries and afterwards on well-vascularized tissues in otolaryngology, gynecology, obstetrics, urology, dentistry, ophthalmology and plastic surgery.
2. Prevention and treatment of capillary bleeding of various etiologies and locations: hematuria, metrorrhagia, primary menorrhagia, menorrhagia in women using intrauterine contraceptives, nosebleeds, bleeding gums.

VALERIAN TINCTURE

tincture for oral use, in 50 ml vials in pack No. 1

Active substance. Ethanolic extract from valerian rootstocks with roots with a root-to-extract ratio of 1:5.

Therapeutic indications

The tincture is indicated as a sedative in case of functional disorders of nervous system (neurasthenia and sleep disturbance).

The use for the indicated purposes is based only on the experience of long-term use.

PEONY TINCTURE

tincture in 50 ml vials in pack No. 1

Active substance. Ethanolic extract (with the ratio of 1:10) from a mixture of peony grass and rootstocks with roots in equal proportions.

Contains no less than 35% (v/v) ethyl alcohol.

Therapeutic indications

The tincture is indicated during the combined therapy of functional disorders of central nervous system (sleep disorders and neurasthenia).

The use for the indicated purposes is based only on the experience of long-term use.

LEONURUS TINCTURE

tincture for oral use, in 50 ml vials in pack No. 1

Active substance. Extract from Leonurus grass with a grass-to-extract ratio of 1:10 (extractant – 70% v/v ethyl alcohol).

Therapeutic indications

During the combined therapy of functional disorders of nervous system (neurasthenia and sleep disturbance); during the combined therapy of functional disorders of cardiac activity. The use for the indicated purposes is based only on the experience of long-term use.

SEDANOL

0tincture for oral use, in 50 ml vials in pack No. 1

Active substances per 50 ml:

Ethanolic extract from Leonurus grass (with the ratio of 1:10) – 15 ml.
Ethanolic extract from rootstocks with valerian roots (with the ratio of 1:5) – 15 ml.
Ethanolic extract from St. John's wort (with the ratio of 1:5) (diagiperon) – 10 ml.
Ethanolic extract from Polemonium rootstocks with roots (with the ratio of 1:5) – 10 ml.

Therapeutic indications

The tincture is indicated for mild functional disorders of nervous system (neurasthenia and sleep disturbances).

HEARTDROPS

50 ml tincture for oral use in pack No. 1

Active substances per 50 ml:

valerian tincture (spirit extraction from valerian rootstocks with roots (at the ratio of 1 to 5)) – 17 ml.
Leonurus tincture (ethanolic extract from Leonurus grass (with the ratio of 1:5)) – 16.5 ml.
Hawthorn tincture (ethanolic extract from hawthorn berries (with the ratio of 1:10)) – 16.5 ml.

Therapeutic indications

During the combined therapy of functional disorders of central nervous system (sleep disorders and neurasthenia).
During the combined therapy of functional disorders of cardiovascular activity.
The use for the indicated purposes is based only on the experience of long-term use.

DIAFERRUM

capsules in jars No. 30 in pack No. 1

Active substances per capsule:

Iron as ferrum (II) asparaginate	- 31 mg
Iron as ferrum (II) glycinate stabilized by ascorbic acid	- 14 mg
Ascorbic acid	- 40 mg

Therapeutic indications

Treatment and prevention of iron-deficiency anemia.



SODIUM CHLORIDE

9 mg/ml solution for injections in 5 ml ampoules in pack No. 5x2

Active substance per 1 ml of solution: sodium chloride – 9 mg.

Therapeutic indications

Dissolution and dilution of drugs.

ROTATIT

liquid extract for topical use for treatment of infections of throat and mouth in 50 ml vials in pack No. 1

Active substances: liquid extract from a mixture (with the ratio of 2:1:1) of chamomile blossoms, calendula blossoms, yarrow grass (DER: with the ratio of 1:3.6), extractant – 70% ethyl alcohol.

Therapeutic indications

During the combined therapy of inflammatory diseases of the oral cavity (gingivitis, stomatitis, periodontitis) in dentistry.

Indicated for use in adults and children over the age of 12.

The use for the indicated purposes is based only on the experience of long-term use.

ROTATIT-PLUS

tincture for topical use for treatment of infections of throat and mouth in 50 ml vials in pack No. 1

Active substances: rotatit (liquid extract from a mixture (with the ratio of 2:1:1) of chamomile flowes, calendula flowers, yarrow grass (DER: with the ratio of 1: 3.2)) – 30 ml.

Diagiperon (tincture from a grass of common St. John's wort (DER: with the ratio of 1: 4.4)) – 10 ml.

Tincture from leaves of garden sage (DER: with the ratio of 1:3.2) – 10 ml.

Therapeutic indications

Rotatit-PLUS is indicated for treatment of inflammatory diseases of the oral cavity (gingivitis, stomatitis, periodontitis) and pharynx (pharyngitis, tonsillitis) during the combined therapy. The use for the indicated purposes is based only on the experience of long-term use.

Rotatit-PLUS is indicated for treatment of adults and children over the age of 18.

The drug exposure reduces the risk of inflammatory processes in the oral cavity during inflammation, redness and swelling of tissues around the teeth due to the biologically active substances constituting the drug.

OXYTOCIN

5 IU/ml solution for intravenous and intramuscular injection in 1 ml ampoules in pack No. 5x2

Active substance per ampoule (1 ml) contains 5 IU of oxytocin.

Therapeutic indications

It is indicated during the antepartum period:
Induction of labor for medical reasons, for example, in cases of prolonged pregnancy, premature rupture of membranes, hypertension caused by pregnancy (preeclampsia).
Stimulation of labor in primary and secondary labor weakness.
At the early pregnancy stages as an adjuvant therapy for incomplete, inevitable or missed abortions.
It is indicated during the postpartum period:
During caesarean section only after fetal extraction.
Prevention and treatment of postpartum uterine atony and bleeding.

DIAVITOL

gel for topical use in a 30 g tube, in a 30 g jar in pack No. 1

Active substance per 30 g pack: diavitol – 0.12 g.

The drug is an ultrafiltrate of the blood of veal calves.

Therapeutic indications

minor injuries;
venous ulcers;
1st and 2nd degree burns;
frostbite.



WATER FOR INJECTION

solvent for preparation of drug dosage forms for injections, in 5 ml ampoules in pack No. 5x2.

Contents. 5 ml water for injection.

Therapeutic indications

Water for injection is used for preparation of drug solutions under aseptic conditions, which are not subjected to further sterilization.

CALENDULA TINCTURE

tincture for external and topical use for treatment of infections of throat and mouth in 50 ml vials in pack No. 1

Active substance. Ethanolic extract from chopped Calendula marigold flowers with the ratio of 1:10.

Therapeutic indications

The tincture is intended for rinsing during the combined therapy of inflammatory diseases of the oral cavity (gingivitis, stomatitis, periodontitis) and throat (tonsillitis), symptomatic treatment of mild inflammatory skin processes and small flesh wounds.

B-GAMMA

solution for intramuscular injection in 2 ml ampoules in pack No. 5x2

Active substances per ampoule: thiamine hydrochloride – 100.0 mg, pyridoxine hydrochloride – 100.0 mg, cyanocobalamin – 1.0 mg, lidocaine hydrochloride – 20.0 mg.

Therapeutic indications

Neurological disorders caused by vitamins B1, B6 and B12 deficiency, which cannot be removed by dietary correction.

DIABAR

200 g suspension for oral use, in bottles or vials in pack No. 1

Active substance per 200 g: barium sulfate for fluoroscopy – 119.1 g.

Therapeutic indications

X-ray of the esophagus, stomach and intestinal tract, including by double contrast method.

SVETON

100 ml, 240 ml solution for contact lenses of all types in pack No. 1

Active substance. Sodium chloride, boric acid, glycerin, Trilon B, water soluble methylcellulose or hydroxyethylcellulose, sodium tetraborate, purified water.

Therapeutic indications

The solution is indicated for cleaning, rinsing, moisturizing and storing contact lenses of all types

YANTARIN

capsules 500 mg each in bottle No. 30

Active substance per capsule: succinic acid – 160 mg, ascorbic acid – 100 mg.

Therapeutic indications

The capsules are indicated to maintain functional activity of the body within physiological limits. An additional source of succinic acid, ascorbic acid (vitamin C).

For notes

Manufacturer: Ferein Open Joint Stock Company
52A, S. Kovalevskaya Lane, 220014, Minsk, Republic of Belarus
Tel. +375 17 222-97-73, 213-12-58
E-mail: sales@ferane.by